Nkarta Inc. Common Stock (NKTX)
Stock · NASDAQ · Health Care
$2.76as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$2.27
Industry
Biotechnology: Pharmaceutical Preparations
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutro…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 106
- Website
- www.nkartatx.com
Fundamentals
- 1-day range
- $2.24$2.34
- Market cap
- $163.84M
- P/E (trailing)
- —
- P/E (forward)
- -1.33
- EPS (trailing)
- $-1.59
- Dividend yield
- —
- Beta
- 0.94
- Avg. volume
- 658.1K
52-week range
$1.7$3.72
Next earnings: November 10, 2026 · EPS estimate $-0.37confirmed
Forecasts
6 analyst ratings
Buy 100%
Hold 0%
Sell 0%
1-year price forecast
High
$14
+407.2%
Median
$10.5
+280.4%
Low
$9
+226.1%
Nkarta Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NKTXNkarta Inc. Common Stock$2.76▲ 0.36%Market cap $163.84MP/E —$1.7$3.72
- INDPIndaptus Therapeutics Inc. Common Stock$1.15▼ 0.86%Market cap $166.55MP/E —
- PEPGPepGen Inc. Common Stock$3.09▲ 0.49%Market cap $166.70MP/E —
- AARDAardvark Therapeutics Inc. Common Stock$5.71▼ 13.75%Market cap $159.75MP/E —$3.35$17.94
- OKUROnKure Therapeutics Inc. Class A Common Stock$3.78▼ 1.31%Market cap $168.06MP/E —$2.23$5.38
- ARCTArcturus Therapeutics Holdings Inc. Common Stock$15.19▼ 6.06%Market cap $172.81MP/E —$5.5$24.17
- MENSJyong Biotech Ltd. Ordinary Shares$2.37▲ 3.04%Market cap $153.58MP/E —$1.43$67
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NKTX Nkarta Inc. Common Stock | $163.84M | — | $2.76 | ▲ 0.36% | $1.7$3.72 |
| INDP Indaptus Therapeutics Inc. Common Stock | $166.55M | — | $1.15 | ▼ 0.86% | |
| PEPG PepGen Inc. Common Stock | $166.70M | — | $3.09 | ▲ 0.49% | |
| AARD Aardvark Therapeutics Inc. Common Stock | $159.75M | — | $5.71 | ▼ 13.75% | $3.35$17.94 |
| OKUR OnKure Therapeutics Inc. Class A Common Stock | $168.06M | — | $3.78 | ▼ 1.31% | $2.23$5.38 |
| ARCT Arcturus Therapeutics Holdings Inc. Common Stock | $172.81M | — | $15.19 | ▼ 6.06% | $5.5$24.17 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $153.58M | — | $2.37 | ▲ 3.04% | $1.43$67 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stifel Maintains Buy on Nkarta, Lowers Price Target to $10Benzinga · 8/14/2026
- HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14Benzinga · 8/11/2026
- Nkarta Q2 EPS $(0.54) Misses $(0.38) EstimateBenzinga · 8/10/2026
Insider Activity
Insider Actions →Acquired
296.0K
Disposed
1.8K
- Paul J. Hastings · June 18, 2026 · Sale1.8K @ $2.71
- Vratsanos George · June 10, 2026 · Grant37.0K
- Scheiner Zachary · June 10, 2026 · Grant37.0K
- Thedinga Angela · June 10, 2026 · Grant37.0K
- Ali Behbahani · June 10, 2026 · Grant37.0K
- Dybbs Michael · June 10, 2026 · Grant37.0K
- George Simeon · June 10, 2026 · Grant37.0K
- RA Capital Healthcare Fund LP · June 10, 2026 · Grant37.0K
- Leone D. Patterson · June 10, 2026 · Grant37.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 56.61M
- Total value held
- $115.93M
- Institutional holders
- 121
Top holders this quarter
- Unknown10.81M
- Unknown4.51M
- Unknown3.57M
- Unknown3.51M
- Unknown3.33M
- Unknown3.15M
- Unknown2.52M
- Unknown2.08M
- Unknown2.05M
- Unknown2.01M
See the full, filterable feed with live charts on the MarketWall dashboard.